PTC Therapeutics (NASDAQ:PTCT) CFO Sells $207,525.12 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CFO Pierre Gravier sold 2,992 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total transaction of $207,525.12. Following the completion of the sale, the chief financial officer directly owned 87,318 shares in the company, valued at approximately $6,056,376.48. This trade represents a 3.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Pierre Gravier also recently made the following trade(s):

• On Tuesday, January 6th, Pierre Gravier sold 2,139 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total transaction of $164,596.05.

PTC Therapeutics Trading Up 1.1%

Shares of NASDAQ:PTCT opened at $70.66 on Monday. The firm’s 50 day moving average is $74.91 and its two-hundred day moving average is $68.14. The firm has a market capitalization of $5.85 billion, a P/E ratio of 9.13 and a beta of 0.48. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). The business had revenue of $164.68 million during the quarter, compared to the consensus estimate of $281.45 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The business’s quarterly revenue was down 22.7% compared to the same quarter last year. During the same period last year, the company earned ($0.85) earnings per share. Analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PTCT. Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Wells Fargo & Company dropped their price target on shares of PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating on the stock in a research report on Friday. Wall Street Zen lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Barclays upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $68.00 to $119.00 in a research note on Tuesday, January 27th. Finally, Royal Bank Of Canada cut their target price on PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating for the company in a research report on Friday. Ten analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $80.73.

Institutional Trading of PTC Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in PTCT. UMB Bank n.a. acquired a new stake in PTC Therapeutics during the fourth quarter valued at approximately $26,000. Smartleaf Asset Management LLC increased its holdings in shares of PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 236 shares in the last quarter. Optiver Holding B.V. lifted its position in shares of PTC Therapeutics by 96.5% during the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 249 shares during the last quarter. Comerica Bank boosted its stake in shares of PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 469 shares in the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in shares of PTC Therapeutics in the 4th quarter worth $41,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.